These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 11961205

  • 1. Molecular targets of arsenic trioxide in malignant cells.
    Miller WH.
    Oncologist; 2002; 7 Suppl 1():14-9. PubMed ID: 11961205
    [Abstract] [Full Text] [Related]

  • 2. Arsenic trioxide: mechanisms of action.
    Davison K, Mann KK, Miller WH.
    Semin Hematol; 2002 Apr; 39(2 Suppl 1):3-7. PubMed ID: 12012315
    [Abstract] [Full Text] [Related]

  • 3. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL.
    Liu Q, Hilsenbeck S, Gazitt Y.
    Blood; 2003 May 15; 101(10):4078-87. PubMed ID: 12531793
    [Abstract] [Full Text] [Related]

  • 4. Interaction between arsenic trioxide and human primary cells: emphasis on human cells of myeloid origin.
    Binet F, Antoine F, Girard D.
    Inflamm Allergy Drug Targets; 2009 Mar 15; 8(1):21-7. PubMed ID: 19275690
    [Abstract] [Full Text] [Related]

  • 5. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide.
    Slack JL, Waxman S, Tricot G, Tallman MS, Bloomfield CD.
    Oncologist; 2002 Mar 15; 7 Suppl 1():1-13. PubMed ID: 11961204
    [Abstract] [Full Text] [Related]

  • 6. Mechanisms of action of arsenic trioxide.
    Miller WH, Schipper HM, Lee JS, Singer J, Waxman S.
    Cancer Res; 2002 Jul 15; 62(14):3893-903. PubMed ID: 12124315
    [Abstract] [Full Text] [Related]

  • 7. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.
    Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, Lamph WW, Waxman S, Pelicci PG, Lo Coco F, Avvisati G, Testa U, Peschle C, Gambacorti-Passerini C, Nervi C, Miller WH.
    J Natl Cancer Inst; 1998 Jan 21; 90(2):124-33. PubMed ID: 9450572
    [Abstract] [Full Text] [Related]

  • 8. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia.
    Lengfelder E, Hofmann WK, Nowak D.
    Leukemia; 2012 Mar 21; 26(3):433-42. PubMed ID: 21904379
    [Abstract] [Full Text] [Related]

  • 9. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
    Zhou GB, Zhang J, Wang ZY, Chen SJ, Chen Z.
    Philos Trans R Soc Lond B Biol Sci; 2007 Jun 29; 362(1482):959-71. PubMed ID: 17317642
    [Abstract] [Full Text] [Related]

  • 10. Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity.
    Dbaibo GS, Kfoury Y, Darwiche N, Panjarian S, Kozhaya L, Nasr R, Abdallah M, Hermine O, El-Sabban M, de Thé H, Bazarbachi A.
    Haematologica; 2007 Jun 29; 92(6):753-62. PubMed ID: 17550847
    [Abstract] [Full Text] [Related]

  • 11. Survivin isoform expression in arsenic trioxide-treated acute promyelocytic leukemia cell line and patients: The odd expression pattern of survivin-2α.
    Zaki Dizaji M, Ghaffari SH, Hosseini E, Alizadeh N, Rostami S, Momeny M, Alimoghaddam K, Ghavamzadeh A.
    Asia Pac J Clin Oncol; 2017 Apr 29; 13(2):e21-e30. PubMed ID: 27770503
    [Abstract] [Full Text] [Related]

  • 12. Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione S-transferase p1-1.
    Wang R, Liu C, Xia L, Zhao G, Gabrilove J, Waxman S, Jing Y.
    Clin Cancer Res; 2012 Dec 15; 18(24):6690-701. PubMed ID: 23082001
    [Abstract] [Full Text] [Related]

  • 13. Mechanistic effects of arsenic trioxide on acute promyelocytic leukemia and other types of leukemias.
    Yousefnia S.
    Cell Biol Int; 2021 Jun 15; 45(6):1148-1157. PubMed ID: 33527587
    [Abstract] [Full Text] [Related]

  • 14. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
    Huan SY, Yang CH, Chen YC.
    Leuk Lymphoma; 2000 Jul 15; 38(3-4):283-93. PubMed ID: 10830735
    [Abstract] [Full Text] [Related]

  • 15. Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies.
    Chou WC, Dang CV.
    Curr Opin Hematol; 2005 Jan 15; 12(1):1-6. PubMed ID: 15604884
    [Abstract] [Full Text] [Related]

  • 16. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
    Wang QQ, Zhou XY, Zhang YF, Bu N, Zhou J, Cao FL, Naranmandura H.
    Oncotarget; 2015 Sep 22; 6(28):25646-59. PubMed ID: 26213848
    [Abstract] [Full Text] [Related]

  • 17. Catalase activity and arsenic sensitivity in acute leukemia.
    Coe E, Schimmer AD.
    Leuk Lymphoma; 2008 Oct 22; 49(10):1976-81. PubMed ID: 18949620
    [Abstract] [Full Text] [Related]

  • 18. Arsenic trioxide: acute promyelocytic leukemia and beyond.
    Bachleitner-Hofmann T, Kees M, Gisslinger H.
    Leuk Lymphoma; 2002 Aug 22; 43(8):1535-40. PubMed ID: 12400595
    [Abstract] [Full Text] [Related]

  • 19. PML/RARalpha fusion protein mediates the unique sensitivity to arsenic cytotoxicity in acute promyelocytic leukemia cells: Mechanisms involve the impairment of cAMP signaling and the aberrant regulation of NADPH oxidase.
    Li L, Wang J, Ye RD, Shi G, Jin H, Tang X, Yi J.
    J Cell Physiol; 2008 Nov 22; 217(2):486-93. PubMed ID: 18636556
    [Abstract] [Full Text] [Related]

  • 20. All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells.
    Liu X, Chen J, Yu S, Yan L, Guo H, Dai J, Zhang W, Zhu J.
    Cell Death Dis; 2017 May 11; 8(5):e2782. PubMed ID: 28492552
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.